Cancer proteomics therapy

The final goal of clinical cancer proteomics is to discover biomarkers for early small cancers, to clarily pathogenesis and carcinogenesis of cancers, and to tailor the therapy for the cancer patients. Although a huge number of reports about the discovery of biomarkers by proteomics has been published, still no biomarker is being used practically in hospitals. However, some kinds of proteins detected in sera Irom cancer patients are expectable as a biomarker (24,37,38,39). 

Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer the HER-2/neu gene and protein. Mol. Cell. Proteomics 2004 3 379-398. 

Pharmacogenomic studies have led to many results that can be used to tailor therapy for cancer patients. Many reports have showed the identification of proteins concerned with drug-resistance proteomically (40,41,42,43,44). In fact, we identified HSP27 as a protein related to resistance to gemcitabine, which is the only effective anti-cancer drug against pancreatic cancer (45,46)... 

New precision technology, based on protein structures and function makes it possible for clinicians to detect cancer earlier than ever and provide individualized treatment. Following the discovery of new proteins and gene maps, cancer researchers believed that proteomics is a revolutionary approach to detect cancer and other major illnesses (e.g., HIV) during their early phases and to tailor individualized therapy. 

Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers Lung cancer classification in the age of targeted therapy. J Clin Oncol 2005 23(14) 3219-3226. Review. 

Lage, H. (2004). Proteomics in cancer cell research an analysis of therapy resistance. Pathol. Res. Pract. 200,105-117. 

Carr, K. M. Rosenblatt, K. Petricoin, E. F. Liotta, L. A., Genomic and proteomic approaches for studying human cancer Prospects for true patient-tailored therapy, Hum. Genomics 2004,... 

Armexin A1 emerged as a promising antigen for the radiolabeled antibody-based imaging and therapy of cancer [100]. In our laboratory, we use terminal perfusion protocols featuring active esters of biotin for the selective chemical labeling of accessible proteins in vascular structures. Biotinylated proteins are then purified from different organs (collected separately) and are submitted to a comparative proteomic analysis [106]. 

Hanash, S.M., Madoz-Gurpide, J., and Misek, D.E., 2002, Identification of novel targets for cancer therapy using expression proteomics. Leukemia 16 478-485. 

Amann, J.M., Lee, ).-W., Roder, H., et d. (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-Une therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. 

---